Safety and efficacy of mycophenolate in COVID-19

Bibliographic Details
Published in:	The Lancet Regional Health - Southeast Asia
Main Authors:	Guangting Zeng, Xiangting Liu, Xia Wang, Hui Li
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772368223001816

Similar Items

Efficacy of MP1032 in hospitalised patients with COVID-19
by: Jing Liu, et al.
Published: (2024-03-01)

Timing and sequence of vaccination against COVID-19 and influenza
by: Jing Liu, et al.
Published: (2023-07-01)

Efficacy and Safety of Mycophenolate Mofetil in Children with Steroid Dependent Nephrotic Syndrome
by: Taek Jin Lim, et al.
Published: (2015-10-01)

Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection
by: Pranav Dalal, et al.
Published: (2009-01-01)

Post COVID‐19 organizing pneumonia treated with mycophenolate mofetil
by: Hui Xin Tan, et al.
Published: (2022-11-01)

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
by: Bing Du, et al.
Published: (2017-07-01)

Comparative efficacy and safety of mycophenolate mofetil and azathioprine in combination with corticosteroids in the treatment of lymphocytic myocarditis
by: R. S. Rud, et al.
Published: (2021-12-01)

Safety and Efficacy of a Preemptive Mycophenolate Mofetil Dose Reduction Strategy in Kidney Transplant Recipients
by: Karim Yatim, MD, et al.
Published: (2024-09-01)

Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis
by: Argyris Tzouvelekis, et al.
Published: (2011-01-01)

Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation
by: O Manuel, et al.
Published: (2007-12-01)

Comparison of the efficacy and safety of low-dose calcineurin inhibitors plus sirolimus plus mycophenolic acid with the standard-dose calcineurin inhibitors plus mycophenolic acid regimen in patients who received kidney transplants
by: Li Li, et al.
Published: (2025-09-01)

Immunotherapy for neuromyelitis optica spectrum disorder: a comparative analysis of efficacy and safety of azathioprine, mycophenolate mofetil, tacrolimus, and rituximab
by: Jing Zhou, et al.
Published: (2025-04-01)

Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review.
by: Mohammed A Omair, et al.
Published: (2015-01-01)

Safety and efficacy of mycophenolate mofetil in treating neuromyelitis optica spectrum disorders: a protocol for systematic review and meta-analysis
by: Yang Chen, et al.
Published: (2020-11-01)

Efficacy of Mycophenolate in Interstitial Lung Disease Associated with Rheumatoid Arthritis
by: Sindhuja Rajendran, et al.
Published: (2024-01-01)

Covid-19-associated pulmonary aspergillosis in mechanically ventilated patients
by: Guangting Zeng, et al.
Published: (2024-03-01)

Efficacy and safety of oral cyclophosphamide versus mycophenolate mofetil in childhood nephrotic syndrome: an open-label comparative study
by: Gurdeep Singh Dhooria, et al.
Published: (2024-09-01)

Efficacy and safety of mycophenolate mofetil for steroid reduction in neuromyelitis optica spectrum disorder: a prospective cohort study
by: Ritsu Akatani, et al.
Published: (2024-04-01)

Comparative efficacy and safety of mizoribine and mycophenolate mofetil for treating systemic lupus erythematosus: a retrospective cohort study
by: Masahiro Ayano, et al.
Published: (2022-05-01)

Mycophenolate mofetil versus cyclophosphamide plus in patients with connective tissue disease-associated interstitial lung disease: Efficacy and safety analysis
by: Wang Pengfei, et al.
Published: (2023-11-01)

STUDY OF THE EFFICIENCY AND SAFETY OF MYCOPHENOLATE MOFETIL THERAPY IN PATIENTSWITH SYSTEMIC SCLERODERMA
by: O A Koneva, et al.
Published: (2011-08-01)

Mycophenolate mofetil and atherosclerosis
by: Z S Alekberova, et al.
Published: (2009-10-01)

Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats
by: Yichen Jia, et al.
Published: (2018-07-01)

COVID-19 associated pulmonary aspergillosis in critically-ill patients
by: Guangting Zeng, et al.
Published: (2024-07-01)

Long-term efficacy and safety of different corticosteroid courses plus mycophenolate mofetil for autoimmune encephalitis with neuronal surface antibodies without tumor
by: Dong Li, et al.
Published: (2023-07-01)

Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies
by: Corrado Campochiaro, et al.
Published: (2024-04-01)

Comment to “Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry”
by: Guangting Zeng, et al.
Published: (2024-05-01)

Efficacy and safety of mycophenolate mofetil in treating immune‐related hepatitis induced by immune checkpoint inhibitor use: A retrospective study
by: Yukio Kadokawa, et al.
Published: (2023-02-01)

Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal Quality of Life?
by: Kyle M. Gardiner, et al.
Published: (2018-11-01)

Corticosteroid treatment in COVID-19 patients receiving extracorporeal membrane oxygenation: benefit from rational use
by: Guangting Zeng, et al.
Published: (2024-10-01)

Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan® and Mowel® after liver transplantation
by: Vollmar J, et al.
Published: (2015-11-01)

LP-128 Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and azathioprine as maintenance therapies for lupus nephritis: a network meta-analysis
by: Young Ho Lee, et al.
Published: (2023-07-01)

Effectiveness and Safety of Mycophenolate Mophetil in Myasthenia Gravis: A Real-Life Multicenter Experience
by: Claudia Vinciguerra, et al.
Published: (2024-07-01)

Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation
by: Hyeyoung Kim, et al.
Published: (2014-09-01)

1602 Switching from mycophenolate mofetil to mycophenolic acid in SLE patients: Results from the RISE registry
by: Zara Izadi, et al.
Published: (2022-12-01)

Outcome of COVID-19 in patients with rheumatic and inflammatory diseases treated with mycophenolic acid: data from the French RMD COVID-19 cohort
by: Eric Hachulla, et al.
Published: (2022-09-01)

Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis
by: Sally Singh, et al.
Published: (2024-06-01)

Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients
by: Jun Zhang, et al.
Published: (2017-05-01)

Mycophenolate Mofetil-Induced Pneumatosis Intestinalis
by: Daphne Moutsoglou, et al.
Published: (2024-01-01)

Mycophenolate mofetil in giant cell arteritis
by: Anne Pankow, et al.
Published: (2023-11-01)